dexmedetomidine hydrochloride · Bioxcel · NDA 215390

Igalmi

Earliest generic entry, as listed · earliest of 2 marketed strengths
12 Jan 2043

Blocked by patent: US 11806334, US 11998528, US 12090140, US 12138247, US 12364683. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.

Listed patents · 14 unexpired

15 Orange Book listing rows for 14 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.

PatentClaimsExpires
US 11806334use U-3725 · sets the listed date12 Jan 2043
US 11998528use U-3935 · sets the listed date12 Jan 2043
US 12090140use U-3986 · sets the listed date12 Jan 2043
US 12138247use U-4029 · sets the listed date12 Jan 2043
US 12364683use U-4029 · sets the listed date12 Jan 2043
US 11890272use U-3756, U-393517 Jul 2040
US 11890272 listing rowuse U-375617 Jul 2040
US 11890272 listing rowuse U-393517 Jul 2040
US 11998529use U-393517 Jul 2040
US 12109196use U-393517 Jul 2040
US 10792246drug product, use U-335026 Jun 2039
US 11478422drug product26 Jun 2039
US 11497711drug product, use U-364526 Jun 2039
US 11517524drug product, use U-364526 Jun 2039
US 11786508use U-369829 Dec 2037
US 11839604use U-375629 Dec 2037

Exclusivities · 1 unexpired

M-82miscellaneous (3 years)19 Nov 2028

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 2

NDA · productFormStrengthListed expiry
215390 · 001 · RLDfilm, buccal, sublingualEQ 0.12MG BASE12 Jan 2043
215390 · 002 · RLDfilm, buccal, sublingualEQ 0.18MG BASE12 Jan 2043